BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37310241)

  • 41. Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).
    Vives N; Binefa G; Vidal C; Milà N; Muñoz R; Guardiola V; Rial O; Garcia M
    Prev Med; 2022 Feb; 155():106929. PubMed ID: 34954239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021.
    Sabatino SA; Thompson TD; White MC; Villarroel MA; Shapiro JA; Croswell JM; Richardson LC
    Prev Chronic Dis; 2023 Oct; 20():E94. PubMed ID: 37884318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.
    Gupta S; Coronado GD; Argenbright K; Brenner AT; Castañeda SF; Dominitz JA; Green B; Issaka RB; Levin TR; Reuland DS; Richardson LC; Robertson DJ; Singal AG; Pignone M
    CA Cancer J Clin; 2020 Jul; 70(4):283-298. PubMed ID: 32583884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of social determinants of health on colorectal cancer screening and surveillance in the COVID reopening phase.
    Choy AM; Lebwohl B; Krigel A
    Eur J Gastroenterol Hepatol; 2022 Jul; 34(7):739-743. PubMed ID: 35102113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis.
    Zhang J; Cheng Z; Ma Y; He C; Lu Y; Zhao Y; Chang X; Zhang Y; Bai Y; Cheng N
    Clin Colorectal Cancer; 2017 Dec; 16(4):252-263. PubMed ID: 28687458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study.
    Selby K; Jensen CD; Zhao WK; Lee JK; Slam A; Schottinger JE; Bacchetti P; Levin TR; Corley DA
    Clin Transl Gastroenterol; 2019 Feb; 10(2):e00010. PubMed ID: 30829917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
    Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
    Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal adherence with fecal occult blood test screening in community practice.
    Fenton JJ; Elmore JG; Buist DS; Reid RJ; Tancredi DJ; Baldwin LM
    Ann Fam Med; 2010; 8(5):397-401. PubMed ID: 20843880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.
    Singal AG; Gupta S; Tiro JA; Skinner CS; McCallister K; Sanders JM; Bishop WP; Agrawal D; Mayorga CA; Ahn C; Loewen AC; Santini NO; Halm EA
    Cancer; 2016 Feb; 122(3):456-63. PubMed ID: 26535565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colonoscopy screening and surveillance disparities during the COVID-19 pandemic.
    Randle HJ; Gorin A; Manem N; Feustel PJ; Antonikowski A; Tadros M
    Cancer Epidemiol; 2022 Oct; 80():102212. PubMed ID: 35816937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
    Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
    Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.